Palo Alto

The trials here

What the 26 trials at this site are about, from their registry records.

Conditions

• Amyloidosis5 trials
• Chronic lymphocytic leukaemia4 trials
• Liver and biliary tract cancer3 trials
• Dilated cardiomyopathy2 trials
• Gastric and oesophageal cancer2 trials
• Heart failure2 trials
• Kidney cancer2 trials
• Lung cancer2 trials
• Pancreatic cancer2 trials
• Acute lymphoblastic leukaemia1 trial
• Bladder cancer1 trial
• Childhood cancers1 trial
• and 9 more

Phase

• Phase 316 trials
• Phase 1/23 trials
• Phase 23 trials
• Phase 12 trials

Status

• Active, not recruiting11 trials
• Not yet recruiting7 trials
• Recruiting7 trials
• Withdrawn1 trial

Lead sponsor

• AstraZeneca14 trials
• Alexion Pharmaceuticals, Inc.7 trials
• Acerta Pharma BV4 trials
• Arcus Biosciences, Inc.1 trial

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc., Sponsor

• Recruiting

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· Phase 3· AstraZeneca· Source

  Contact: AstraZeneca Clinical AstraZeneca Clinical

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

  NCT07690436· AstraZeneca· Source

• Recruiting

  A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  NCT07647328· Phase 3· AstraZeneca· Source

• Recruiting

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· Phase 3· AstraZeneca· Source

• Recruiting

  ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

  NCT07218887· Phase 1/2· Alexion Pharmaceuticals, Inc.· Source

  Contact: Shannon Schultz

• Recruiting

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Phase 3· Arcus Biosciences, Inc.· Source

  Contact: Medical Director

• Recruiting

  Study of Ravulizumab in Pediatric Participants With Primary IgAN

  NCT07024563· Phase 3· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc. (Sponsor)

• Recruiting

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  NCT06878261· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT06879041· Phase 1· AstraZeneca· Source

• Active, not recruiting

  A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

  NCT06147037· Phase 1· AstraZeneca· Source

• Active, not recruiting

  To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

  NCT06194448· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  NCT06137118· Phase 1/2· AstraZeneca· Source

• Recruiting

  AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

  NCT06219941· Phase 2· AstraZeneca· Source

• Active, not recruiting

  A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)

  NCT05981092· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

  NCT04512235· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

  NCT04504825· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

  NCT03732677· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

  NCT02717611· Phase 2· Acerta Pharma BV· Source

• Active, not recruiting

  A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

  NCT02586857· Phase 1/2· Acerta Pharma BV· Source

• Active, not recruiting

  Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  NCT02477696· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

  NCT02475681· Phase 3· Acerta Pharma BV· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer3 recruiting
• Amyloidosis2 recruiting
• Heart failure2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Dilated cardiomyopathy1 recruiting
• Gastric and oesophageal cancer1 recruiting
• IgA nephropathy1 recruiting
• Kidney cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Recruiting

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· Phase 3· AstraZeneca· Source